Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celgene Joins Troubled MS Club With Refuse To File For Ozanimod From US FDA

Executive Summary

Other multiple sclerosis contenders – including Sanofi's Lemtrada, Acorda's Ampyra, and Merck KgAA's cladribine – have also been RTFed. Question now for Celgene is how long the delay will be. 
Advertisement

Related Content

Keeping Track: First RMAT Approval On The Horizon; Big Weeks For Merck, Lilly And Celgene
FDA Backs Novartis MS Pill Mayzent With Broad Label
Stock Scan February 2018: Wet But Above Water
Keeping Track: Delay (For Celgene), Delay (For Allergan), Goose! (Approval For Lilly)
More Bad News: Celgene Reveals Refuse-To-File Letter For Ozanimod In MS
Refuse-to-File Turns 25: New Guidance Changes In Style, But Not Substance
Celgene Plots Blockbuster Course For Ozanimod
Merck KGaA Rules Out Major M&A, Says MS Pill Mavenclad Will Be Major Earner
Genzyme Lemtrada’s Momentum Halts With FDA “Refuse-To File” Letter
FDA Approves Ampyra Despite Slight Responder Rate and Seizure Risk

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS122611

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel